-
Electronic (PDF)
-
Site License
-
Enterprisewide
Cancer Anorexia - Pipeline Review, H1 2012
Global Markets Direct, June 2012, Pages: 35
Cancer Anorexia – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Cancer Anorexia - Pipeline Review, H1 2012', provides an overview of the Cancer Anorexia therapeutic pipeline. This report provides information on the therapeutic development for Cancer Anorexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Anorexia. 'Cancer Anorexia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Cancer Anorexia.
- A review of the Cancer Anorexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cancer Anorexia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Cancer Anorexia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cancer Anorexia pipeline depth and focus of Cancer Anorexia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Cancer Anorexia Therapeutic Products under Development, Key Players in Cancer Anorexia Therapeutics, Cancer Anorexia Pipeline Overview, Cancer Anorexia Pipeline, Cancer Anorexia Pipeline Assessment
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cancer Anorexia Overview
Therapeutics Development
An Overview of Pipeline Products for Cancer Anorexia
Cancer Anorexia Therapeutics under Development by Companies
Cancer Anorexia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Cancer Anorexia Therapeutics – Products under Development by Companies
Cancer Anorexia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Cancer Anorexia Therapeutics Development
Helsinn Healthcare S.A.
Cancer Anorexia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Marinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Melatonin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enbrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anamorelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Megestrol Acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ghrelin Receptor Agonists - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cancer Anorexia Therapeutics – Drug Profile Updates
Cancer Anorexia Therapeutics – Discontinued Products
Cancer Anorexia – Product Development Milestones
Featured News & Press Releases
Dec 07, 2011: Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program For Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
Aug 24, 2011: Helsinn Therapeutics Initiates Phase III Clinical Program To Evaluate Anamorelin In Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
Nov 03, 2010: Ohr Pharmaceutical Inc. Announces $244,000 Grant Award
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Cancer Anorexia, H1 2012
Products under Development for Cancer Anorexia – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Helsinn Healthcare S.A., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Cancer Anorexia Therapeutics – Drug Profile Updates
Cancer Anorexia Therapeutics – Discontinued Products
List of Figures
Number of Products under Development for Cancer Anorexia, H1 2012
Products under Development for Cancer Anorexia – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
